Nektar Therapeutics
NASDAQ:NKTRBiotechnology
-$1.24 today
- Market cap
- $987.44M
- Beta
- 1.15
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$6.39
Volume 0.71M
Average 1.00M
NKTR Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Nektar TherapeuticsNASDAQ: NKTR
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue declines year over year
Q2 FY2026 revenue of $10.13M fell 9.3% year over year, ahead of the -27.2% change in trailing-twelve-month revenue. Sequentially, it fell 6.7% from the prior quarter. Over 3 fiscal years it compounded at -15.7% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 13 analysts of $40.52M (-26.6%) for the fiscal year ending Dec 2026, a step up from the -43.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $10.13M-6.7% QoQ
- Last fiscal yearDec 2025
- $55.23M-43.9% YoY
- LTMJun 2026
- $54.59M-27.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -9.3% | -12.9% | -3.5 pp |
| 1 year | -43.9% | -26.6% | +17.3 pp |
| 3-year CAGR | -15.7% | -12.3% | +3.4 pp |
| 5-year CAGR | +27.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 55.23M USD
- Year-over-year change
- -43.9%
- 4-year CAGR
- -14.2%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 55.23M | -43.9% |
| FY2024 | 2024-12-31 | 98.43M | +9.2% |
| FY2023 | 2023-12-31 | 90.12M | -2.1% |
| FY2022 | 2022-12-31 | 92.06M | -9.7% |
| FY2021 | 2021-12-31 | 101.91M | — |
Revenue vs competitors
How NKTR compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -27.2% is the 4th highest of 9, against a peer median of -45.7%.
- Over three fiscal years its annual growth of -15.7% compares with a peer median of -4.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $385.76M USD | +15.6% | +27.3% | |
| LTM Mar 2026 | $157.08M USD | +3.1% | -0.1% | |
| LTM Jun 2026 | $117M USD | -55.3% | +30.2% | |
| LTM Jun 2026 | $104.97M USD | -36.1% | -8.6% | |
| LTM Mar 2026 | $72.66M USD | +163.4% | +113.3% | |
| LTM Jun 2026 | $54.59M USD | -27.2% | -15.7% | |
| LTM Mar 2026 | $46.88M USD | -76.3% | -41.5% | |
| LTM Mar 2026 | €37.3M EUR | -74.1% | -34.6% | |
| LTM Jun 2024 | $6.49M USD | — | — | |
| FY2025 | €2.79M EUR | -77.9% | -63.6% | |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding NKTR) | — | -45.7% | -4.4% | |
Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 101.91M | 92.06M | 90.12M | 98.43M | 55.23M |
| Cost of Revenue | 24.9M | 21.64M | 36.64M | 30.69M | 0 |
| Gross Profit | 77.01M | 70.42M | 53.48M | 67.74M | 55.23M |
| Gross Margin | 75.6% | 76.5% | 59.3% | 68.8% | 100.0% |
| Research & Development | 400.27M | 218.32M | 114.16M | 120.91M | 117.33M |
| Selling, General & Admin | 122.84M | 92.33M | 77.42M | 76.75M | 68.67M |
| Operating Expenses | 523.11M | 310.66M | 190.9M | 172.94M | 186M |
| Depreciation & Amortization | 14.15M | 12.2M | 7.82M | 4.39M | 1.03M |
| EBITDA | (461.82M) | (323.87M) | (243.11M) | (86.7M) | (137M) |
| EBITDA Margin | -453.2% | -351.8% | -269.8% | -88.1% | -248.1% |
| Operating Income | (446.1M) | (240.24M) | (137.43M) | (105.2M) | (130.77M) |
| Operating Margin | -437.8% | -261.0% | -152.5% | -106.9% | -236.8% |
| Interest Income | 2.73M | 6.78M | 19.01M | 14.5M | 10.44M |
| Interest Expense | 47.31M | 28.91M | 25.33M | 28.11M | 26.18M |
| Other Income / Expenses | (77.18M) | (124.75M) | (138.83M) | (14M) | (33.44M) |
| Income Before Tax | (523.28M) | (364.98M) | (276.26M) | (119.2M) | (164.21M) |
| Pre-Tax Margin | -513.5% | -396.5% | -306.5% | -121.1% | -297.3% |
| Income Tax Expense | 557K | 3.22M | (200K) | (239K) | (138K) |
| Net Income | (523.84M) | (368.2M) | (276.06M) | (118.96M) | (164.08M) |
| Net Margin | -514.0% | -400.0% | -306.3% | -120.9% | -297.1% |
| EPS (Basic) | (42.90) | (29.51) | (21.79) | (8.68) | (9.73) |
| EPS (Diluted) | (42.90) | (29.51) | (21.79) | (8.68) | (9.73) |
| Weighted Avg Shares | 12.22M | 12.48M | 12.67M | 13.71M | 16.87M |
| Weighted Avg Shares (Diluted) | 12.22M | 12.48M | 12.67M | 13.71M | 16.87M |
Nektar Therapeutics
NASDAQ:NKTR
Intrinsic Alpha fair value
Locked
Current Price
$34.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.